High Vitamin B12 in a Blood Test: Causes (Not Only Supplements) and When It Is Worrying

Laboratories report vitamin B12 (cobalamin) in pg/mL or in pmol/L — always check the unit on your result. The conversion is fixed: 1 pg/mL is about 0.738 pmol/L, so 1000 pg/mL corresponds to roughly 738 pmol/L, and 1 pmol/L is about 1.355 pg/mL. The reference range depends on the method and the laboratory, so the 'upper limit of normal' differs; in the Danish studies we use below the upper limit was set at about 600 pmol/L (roughly 810 pg/mL).

It is worth distinguishing two situations. A result slightly above normal (for example up to 1000–1200 pg/mL) in someone who takes a multivitamin or a B12 preparation is usually nothing to worry about. A result several times the upper limit (several thousand pg/mL) in someone who takes no supplements looks completely different — here the chance that something needs explaining behind the result rises. The higher the level without a supplement explanation, the more sensible the work-up.

Absorption of vitamin B12 from food depends on intrinsic factor and has a limited capacity, but at large oral doses (hundreds to thousands of micrograms) a small fraction is absorbed passively, without intrinsic factor. Injections bypass the digestive tract altogether: after an intramuscular injection serum cobalamin can stay for several days, sometimes longer, at values many times above the reference range. The binding proteins for B12 in blood have a limited capacity, so the excess circulates free or loosely bound and is excreted mainly in urine.

In the Danish paper cited here (Arendt and Nexo, 2012) the share of patients taking B12 rose steeply with the level: about 6% among people with a normal result, already 27% in the 601–1000 pmol/L group and 53% in the group above 1000 pmol/L. In other words, even at very high values roughly half of the patients had a simple explanation and the other half did not. It is that second half that makes the topic one that 'does not mean nothing'.

If you recognise one of the above, the simplest step is often a break in supplementation and a repeat test — in a way and at a time agreed with your doctor, because the time after which the level returns to baseline depends on the dose and the route (after injections it falls more slowly than after tablets). Do not stop B12 on your own if it was prescribed for a diagnosed deficiency, an autoimmune gastric disease or after bariatric surgery.

When there are no supplements, the causes of high B12 fall into several groups. It must be said at once that the mechanism is not fully understood and is probably multifactorial — that is how both the clinical reviews from Aarhus and the review from Strasbourg summarise it. The common thread is a rise in one of the two proteins that carry cobalamin in the blood: haptocorrin (transcobalamin I) or, less often, transcobalamin.

Liver disease. The liver is the main store of B12 in the body. Damage to hepatocytes (cirrhosis, acute and chronic hepatitis, alcoholic liver disease) releases stored cobalamin and binding proteins into the blood. In the PLoS One paper cited, liver disease was associated with very high B12 with an odds ratio of 8.5 (95% CI 3.6–20.2) and alcoholism with an odds ratio of 5.7 (2.8–12.0) — while haptocorrin was raised. That is why liver tests are among the first investigations in unexplained high B12 (we describe them in a separate entry on ALT, AST and GGT).

Kidney disease. With reduced glomerular filtration the excretion and metabolism of transcobalamin change, which can raise total serum B12. The authors of the reviews list renal failure among the stable associations with high B12, although the data are mostly observational and do not settle whether it is a cause or a companion of other disturbances. Creatinine and eGFR are therefore checked as standard.

Blood-forming disorders and cancer. The highest B12 levels have been described in myeloproliferative diseases (for example chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia), in which the increased number and activation of granulocytes raises haptocorrin production. Raised B12 has also been described in solid tumours, especially with liver metastases. This thread is the most worrying for patients, so we devote a separate part to it below — together with an honest statement of the limitations of these studies.

Other associations include autoimmune diseases, chronic lung disease, connective tissue disease and rare inborn defects. Importantly, the Strasbourg review describes a paradox: in some patients with a high B12 concentration symptoms of functional deficiency may occur, because cobalamin is bound to a protein (haptocorrin) that does not release it to the tissues. 'High B12 in the blood' therefore does not automatically mean 'plenty of B12 in the cells'.

How should this be read? The SIR compares the number of cancers in people with high B12 with the number expected in the general population — it is a relative risk, not an absolute one. A high SIR does not mean that most people with high B12 will develop cancer; it means that among them cancers are diagnosed more often than in people of similar age and sex. The authors point out that the risk is concentrated in the first year, which suggests that high B12 is rather a marker of a not-yet-recognised, already existing disease (hence the conclusion about 'detection'), not a risk factor acting over years.

A similar conclusion follows from the clinical review by Arendt and Nexo (2013), who proposed a strategy called 'think the worst first' — first rule out serious diseases (cancer, then liver and kidney disease) before regarding the result as harmless. Caution also requires saying that population data do not imply that a person with a moderately raised B12 and no symptoms needs broad imaging. The scope of tests depends on the level of the result, symptoms, age and risk factors — and is the doctor's decision.

Macro-B12 is a complex of vitamin B12 with an immunoglobulin (antibody) that is not biologically active but 'fools' automated immunoassays and inflates the result. The phenomenon is analogous to known laboratory artefacts such as macroprolactinaemia. A person with macro-B12 may truly have a low or normal B12 level in the tissues and at the same time a high result on the laboratory report — or, paradoxically, symptoms of deficiency.

What does this mean for a patient? If a very high B12 result does not fit the clinical picture (no supplements, no liver or kidney disease, feeling well, other tests normal), the doctor may ask the laboratory to repeat the measurement with PEG precipitation or another method, and sometimes to measure holotranscobalamin or methylmalonic acid. Not all laboratories perform these tests routinely — this is more a hint for the doctor than something a patient should push for with a mildly raised result.

Below we describe the order that follows from the clinical reviews (Arendt and Nexo 2013; Andrès et al. 2013). This is not an official guideline of a Polish scientific society — we do not know of such a document — but only an arrangement of proposals from the literature. The individual plan is always set by the doctor.

Two practical remarks. First, the blood count is the cheapest and most informative test in this situation: an abnormal white cell or platelet count together with high B12 prompts a search for a myeloproliferative disease (we discuss reading results in our entry on the complete blood count). Second, cobalamin can be inflated even by a single injection given several weeks earlier, so it is important to recall carefully everything that was taken.

To our knowledge neither the US Institute of Medicine nor the European EFSA has set a tolerable upper intake level (UL) for vitamin B12, because of its low toxicity even at very high doses and the lack of clear adverse effects in studies. This explains why a high B12 after supplements is rarely a problem in itself.

There are, however, case reports indicating that high doses of B vitamins (especially B6 together with B12) can provoke skin changes of an acne type or inflammation resembling rosacea. In a 2001 report a 17-year-old girl developed a sudden, severe form of rosacea (rosacea fulminans) in temporal association with daily intake of a high dose of B vitamins; the lesions resolved after the supplement was stopped and treatment started. This is a single case, so the conclusion is cautious: if new acne or facial redness appears after starting injections or a B complex, report it to a doctor.

On the other hand, there is no reason to panic if the result is moderately raised, you take supplements, you feel well, and the blood count, liver tests and creatinine are normal. Most such situations do not end in any serious diagnosis — and the cost of basic tests is small. Particular caution is worth keeping in older people, smokers and those who misuse alcohol, because in the Danish study it was precisely cancers related to smoking and alcohol that were over-represented.

To sum up: a high B12 is a result that usually has a simple explanation but should not be ignored if there is no room for supplements in it. The best order is a history of everything containing B12, then basic tests (blood count, liver, kidneys), and only after that — if nothing explains the result — targeted work-up and exclusion of a laboratory error. Fear of cancer is understandable, but population relative-risk figures are not a diagnosis; they are a reason to talk to a doctor, not a reason to panic.